Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	21716
Country	United States

Received	2015-09-08 08:22
Peer-Review Started	2015-09-08 13:24
To Make the First Decision	2015-10-27 11:01
Return for Revision	2015-11-06 15:58
Revised	2015-11-15 02:27
Second Decision	2016-01-20 16:33
Accepted by Journal Editor-in-Chief	2016-01-21 08:11
Accepted by Company Editor-in-Chief	2016-01-29 17:30
Articles in Press	2016-01-29 17:30
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-03-21 10:23
Publish the Manuscript Online	2016-03-30 14:14

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Molecular therapeutics in pancreas cancer
Manuscript Source	Invited Manuscript
All Author List	Vignesh Narayanan and Colin D Weekes
Funding Agency and Grant Number
Corresponding Author	Colin D Weekes, MD, PhD, Division of Medical Oncology, Department of Medicine, Developmental Therapeutics Program, University of Colorado Cancer Center, University of Colorado School of Medicine, 12801 E. 17th Avenue, Aurora, CO 80045, United States. colin.weekes@ucdenver.edu
Key Words	Pancreas neoplasm; Vaccines; Targeted therapy; Immunotherapy; Kirsten rat sarcoma oncogene
Core Tip	The treatment of pancreas ductal adenocarcinoma is in an exciting phase due to a tremendous surge in knowledge regarding the molecular mechanisms that underlie pancreas cancer that has fueled interest in devising novel strategies to target signal transduction factors downstream to kirsten rat sarcoma oncogene, desmoplastic tumor stroma and cancer stem cells. Furthermore, immunotherapy by utilizing vaccines and immune checkpoint inhibitors is gaining momentum. Alluring results from studies evaluating molecularly targeted therapies have not only proven the feasibility of this approach but are also indicative of a paradigm shift in management of pancreatic cancer in the near future.
Publish Date	2016-03-30 14:14
Citation	Narayanan V, Weekes CD. Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol 2016; 8(4): 366-379
URL	http://www.wjgnet.com/1948-5204/full/v8/i4/366.htm
DOI	http://dx.doi.org/10.4251/wjgo.v8.i4.366

Full Article (PDF)	WJGO-8-366.pdf
Full Article (Word)	WJGO-8-366.doc
Manuscript File	21716-Review.docx
Answering Reviewers	21716-Answering reviewers.pdf
Audio Core Tip	21716-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	21716-Conflict-of-interest statement.pdf
Copyright License Agreement	21716-Copyright assignment.pdf
Peer-review Report	21716-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	21716-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	21716-Scientific misconduct check.pdf
Scientific Editor Work List	21716-Scientific editor work list.pdf